Safety and Efficacy of PD-1/PD-L1 Inhibitors in Cancer Patients With Preexisting Autoantibodies
Open Access
- 16 May 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 893179
- https://doi.org/10.3389/fimmu.2022.893179
Abstract
Background: Programmed cell death protein-1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitors therapy is now a routine scheme in cancers. However, the effect of preexisting autoantibodies on the safety and efficacy of PD-1/PD-L1 inhibitors in cancer patients is not well understood. Methods: The present retrospective cohort study evaluated the safety and efficacy of PD-1/PD-L1 inhibitors in patients with preexisting autoantibodies. Patients who received PD-1/PD-L1 inhibitors in the Department of Medical Oncology, Peking Union Medical College Hospital between November 2017 and August 2021 were reviewed. Results: 67 (37.9%) of the 177 patients, 27 (20.3%) of the 133 patients, and 16 (11.0%) of 146 patients who received PD-1/PD-L1 inhibitors were positive for ANA, anti-Ro52, and antithyroid antibodies, respectively. Preexisting ANA and anti-Ro52 antibody were not associated with the increased risk of immune-related adverse events (irAEs), while thyroid dysfunction was more frequent in patients with positive antithyroid antibody (75.0% versus 13.8%, p < 0.001). The median progression-free survival (PFS, 13.1 versus 7.0 months, p = 0.015) was significantly longer in the ANA-positive patients, while the median overall survival (OS, 14.5 versus 21.8 months, p = 0.67) did not differ significantly between the ANA-positive and ANA-negative groups. Moreover, the preexisting anti-Ro52 and antithyroid antibodies were not significantly associated with PFS and OS. Conclusions: The presence of ANA and anti-Ro52 antibody were not associated with a higher risk of irAEs, whereas patients positive for antithyroid antibody should monitor closely immune-related thyroid dysfunction. Preexisting ANA might be a predictor of longer PFS, while anti-Ro52 and antithyroid antibodies had no significant effect on survival outcomes in patients receiving PD-1/PD-L1 inhibitors therapy.This publication has 29 references indexed in Scilit:
- Antinuclear antibodies and cancer: A literature reviewCritical Reviews in Oncology/Hematology, 2018
- Low positive rate of serum autoantibodies in colorectal cancer patients without systemic rheumatic diseasesAutoimmunity, 2016
- Humoral Autoimmune Response to IGF2 mRNA‐Binding Protein (IMP2/p62) and Its Tissue‐Specific Expression in Colon CancerScandinavian Journal of Immunology, 2013
- Prevalence and sociodemographic correlates of antinuclear antibodies in the United StatesArthritis & Rheumatism, 2012
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Clinical significance of elevated antinuclear antibody test in patients with Hodgkin's and Non-Hodgkin's lymphoma: a single center experience.2008
- The serological pattern of autoantibodies to the Ro52, Ro60, and La48 autoantigens in primary Sjögren's syndrome patients and healthy controlsScandinavian Journal of Rheumatology, 2005
- Antinuclear antibodies as potential markers of lung cancer.1999
- Human neoplasms elicit multiple specific immune responses in the autologous host.Proceedings of the National Academy of Sciences of the United States of America, 1995
- Antinuclear Antibodies: Diagnostic Markers for Autoimmune Diseases and Probes for Cell BiologyAdvances in Immunology, 1989